FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia

September 13, 2018 -- The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news